Results 81 to 90 of about 12,862 (201)
Hepatitis E Virus Drug Development
Viruses, 2019 Hepatitis E virus (HEV) is an underestimated disease, leading to estimated 20 million infections and up to 70,000 deaths annually. Infections are mostly asymptomatic but can reach mortality rates up to 25% in pregnant women or become chronic in ...
Volker Kinast +3 more
doaj +1 more source
DEN Open, Volume 6, Issue 1, April 2026.Abstract While hepatocellular carcinoma (HCC) often invades the portal or hepatic vein to form tumor thrombus, tumor thrombus in the bile duct is rare. In such cases, differentiation from intrahepatic cholangiocarcinoma is difficult, and the tumor often appears as a smooth, yellowish‐white, polypoid mass within the bile duct lumen.
Keisuke Kinoshita +9 more
wiley +1 more source
, 2018 Pooled risk ratio of sustained virological response at week 12 after the end of treatment between sofosbuvir plus ledipasvir with ribavirin and sofosbuvir plus ledipasvir.
Thunyarat Anothaisintawee (840641) +4 more
core +1 more source
Characteristics of patients completed sofosbuvir-daclatasvir treatment cascade (n = 184).
, 2021 Characteristics of patients completed sofosbuvir-daclatasvir treatment cascade (n = 184).
Kuntjoro Harimurti (10035887) +3 more
core +1 more source
The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
One Health & Risk Management, 2020 Introduction. Viral hepatitis C (HCV) is a significant global health problem. The risk of developing chronic HCV is up to 80% of patients, of whom 10-20% can develop liver cirrhosis or hepatocellular carcinoma which can lead to death.
Irina RUSU +2 more
doaj +1 more source
TDM-guided Crushed Sofosbuvir-velpatasvir Treatment: A case study
, 2020 International audienceIn this study, the authors report the case of a patient diagnosed with hepatitis C virus who was treated with sofosbuvir-velpatasvir (400/100 mg).
Charlotte Pronier +15 more
core +1 more source
Changing the face of hepatitis C management – the design and development of sofosbuvir
Drug Design, Development and Therapy, 2015 Bennett C Noell,* Siddesh V Besur,* Andrew S deLemos Department of Medicine, Center for Liver Diseases and Transplantation, Carolinas Medical Center, Charlotte, NC, USA *These authors contributed equally to this work Abstract: The availability of
Noell BC, Besur SV, deLemos AS
doaj
Molecules, 2019 A simple, fast and highly sensitive RP-UPLC-MS/MS method was developed and validated for the simultaneous determination of sofosbuvir (SR) and its metabolite GS331007 in human plasma using ketotifen as an internal standard (IS).
Mohammad H. Semreen +3 more
doaj +1 more source
Comparison of nominal and PPP-adjusted prices of sofosbuvir and ledipasvir/sofosbuvir.
, 2016 Fig 1 shows the nominal (USD FOREX) and PPP-adjusted (USD PPP) prices of (A) sofosbuvir and (B) ledipasvir/sofosbuvir, with and without a 23% rebate (or price reduction).
Peter Beyer (21528) +6 more
core +1 more source